


L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:142712 CAPLUS Full-text
 DN 136:200186
 TI Preparation of dibenzo[b,e]azepines as $\alpha\text{V}\beta 3$ integrin ligands
 IN Geneste, Herve; Kling, Andreas; Lauterbach, Arnulf; Graef, Claudia
 Isabella; Subkowski, Thomas; Hornberger, Wilfried
 PA Basf Aktiengesellschaft, Germany
 SO PCT Int. Appl., 157 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014320	A2	20020221	WO 2001-EP9224	20010809
	WO 2002014320	A3	20020725		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10039998	A1	20020221	DE 2000-10039998	20000811
	AU 2001091756	A5	20020225	AU 2001-91756	20010809
	CA 2419078	AA	20030210	CA 2001-2419078	20010809
	EP 1307443	A2	20030507	EP 2001-971899	20010809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004506637	T2	20040304	JP 2002-519460	20010809
	US 2004077638	A1	20040422	US 2003-344449	20030908
PRAI	DE 2000-10039998	A	20000811		
	DE 2000-10028575	A	20000614		
	WO 2001-EP9224	W	20010809		
OS	MARPAT 136:200186				
GI					



AB The invention relates to novel compds. which bind to integrin receptors, in particular as ligands for the $\alpha\text{V}\beta 3$ integrin receptor, the use thereof and pharmaceutical preps. containing said compds. BGL [L = UT; T = CO₂H, group hydrolizable to CO₂H, isostere of CO₂H; U = Xa(CR₁R₂)_b, CR₁:CR₂, C.tplbond.C, etc.; a = 0, 1; b = 0-2; X = CR₃R₄, NR₅, O, S; R₁-R₄ = T, H, OH, CONH₂, halo, amino, substituted alkyl, alkenyl, alkynyl, cycloalkyl, alkylaminocarbonyl, etc.; R₅ = H, (substituted) alkyl, cycloalkyl, alkoxy, carbonyl, alkylsulfonyl, etc.; G = Q1; Ar = atoms to form a (substituted) (anellated) (heterocyclic) 3-10 membered aryl ring; D = atoms to form a (substituted) (anellated) (unsatd.) (aromatic) 3-10 membered (heterocyclic) ring; X = CR₁₁, N, C; W = YNR₁₅; Y = CO, CS, C:NR₁₂, CR₁₃R₁₄; R₁₁ = H, halo, OH, (substituted) alkyl, alkoxy; R₁₂ = H, OH, (substituted) alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy; R₁₃, R₁₄ = H, (substituted) alkyl, alkenyl, alkynyl, alkoxy; R₁₃R₁₄ = OCH₂CH₂O, OCH₂O, (substituted) cycloalkyl; R₁₅ = R₁₅₁, AR₁₅₂, etc.; R₁₅₁ = COR₁₅₂, CSR₁₅₂, NO₂, tetrazolyl, etc.; R₁₅₂ = H, (substituted) cycloalkyl, aryl, heteroaryl, etc.; R₁₅₃ = H, OH, (substituted)


alkyl, alkoxy, aralkyl, aralkoxy, etc.; B = structure element containing ≥ 1 atom which can function as an acceptor in H bond formation under physiol. conditions], were prepared as $\alpha V\beta 3$ integrin ligands (no data). Thus, ethyldiisopropylamine and HATU were added to a 0° solution of 11-(2-methoxy-2-oxoethyl)-5-methyl-6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepine-3-carboxylic acid (preparation given) in CH_2Cl_2 ; the mixture was stirred 1 h at 0° and 7-(4-aminobutyl)-1,2,3,4-tetrahydro[1,8]naphthyridine bistrifluoroacetate and ethyldiisopropylamine were added followed by stirring for 1 h at 0° overnight at room temperature to give Me [5-methyl-6-oxo-3-[[[4-[5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl]butyl]amino]carbonyl]-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl]acetate.

IT 400712-67-6P 400712-68-7P 400712-69-8P
 400712-70-1P 400712-71-2P 400712-72-3P
 400712-73-4P 400712-74-5P 400712-75-6P
 400712-76-7P 400712-77-8P 400712-78-9P
 400712-79-0P 400712-80-3P 400712-81-4P
 400712-82-5P 400712-83-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of dibenzoazepines as $\alpha V\beta 3$ integrin ligands)


RN 400712-67-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[4-(2-pyridinylamino)butoxy]- (9CI) (CA INDEX NAME)



RN 400712-68-7 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[3-(2-pyridinylamino)propoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 400712-69-8 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 400712-70-1 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[[[3-(2-pyridinylamino)propyl]amino]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 400712-71-2 CAPLUS

CN Acetic acid, [3-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]carbonyl]-5,6-dihydro-5-methyl-6-oxo-11H-dibenz[b,e]azepin-11-ylidene]-, methyl ester (9CI) (CA INDEX NAME)




RN 400712-72-3 CAPLUS

CN Acetic acid, [3-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]carbonyl]-5,6-dihydro-5-methyl-6-oxo-11H-dibenz[b,e]azepin-11-ylidene]- (9CI) (CA INDEX NAME)



RN 400712-73-4 CAPLUS


CN Acetic acid, [5,6-dihydro-5-methyl-6-oxo-3-[3-(2-pyridinylamino)propoxy]-11H-dibenz[b,e]azepin-11-ylidene]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 400712-74-5 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 400712-75-6 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[5-(1H-benzimidazol-2-ylmethyl)amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 400712-76-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[[[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400712-77-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[[[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 400712-78-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[trans-4-(1H-benzimidazol-2-ylamino)cyclohexyl]methyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 400712-79-0 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[trans-4-(1H-benzimidazol-2-ylamino)cyclohexyl]methyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 400712-80-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[[[5-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)pentyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 400712-81-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[[[5-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)pentyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 400712-82-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[4-(1H-benzimidazol-2-ylamino)butyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 400712-83-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[4-(1H-benzimidazol-2-ylamino)butyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo- (9CI) (CA INDEX NAME)



IT 400712-92-7P 400712-93-8P 400712-94-9P

400712-95-0P 400712-96-1P 400712-99-4P


400713-00-0P 400713-04-4P 400713-05-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dibenzoazepines as $\alpha\text{V}\beta 3$ integrin ligands)


RN 400712-92-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-3-[4-[(1-oxido-2-pyridinyl)amino]butoxy]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 400712-93-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[4-(2-pyridinylamino)butoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 400712-94-9 CAPLUS

CN Acetic acid, [5,6-dihydro-5-methyl-3-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-6-oxo-11H-dibenz[b,e]azepin-11-ylidene]-, methyl ester (9CI) (CA INDEX NAME)




RN 400712-95-0 CAPLUS

CN Acetic acid, [5,6-dihydro-5-methyl-6-oxo-3-[3-(2-pyridinylamino)propoxy]-11H-dibenz[b,e]azepin-11-ylidene]-, methyl ester (9CI) (CA INDEX NAME)




RN 400712-96-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[3-(2-pyridinylamino)propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 400712-99-4 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 400713-00-0 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[[[3-

(2-pyridinylamino)propyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 400713-04-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 400713-05-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[1H-benzimidazol-2-ylmethyl)amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:97692 CAPLUS Full-text
 DN 137:103383
 TI Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel
 potent and selective $\alpha\text{V}\beta 3$ antagonists
 AU Kling, Andreas; Backfisch, Gisela; Delzer, Jurgen; Geneste, Herve; Graef,
 Claudia; Holzenkamp, Uta; Hornberger, Wilfried; Lange, Udo E. W.;
 Lauterbach, Arnulf; Mack, Helmut; Seitz, Werner; Subkowski, Thomas
 CS Knoll GmbH, Ludwigshafen, D-67008, Germany
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(3), 441-446
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 137:103383
 GI



AB Substituted oxodibenzazepineacetic acids substituted with guanidines or
 guanidine pharmacophores such as I are prepared as potential $\alpha\text{V}\beta 3$ (vitronectin
 receptor) antagonists. The oxodibenzazepineacetic acid core II is prepared in
 5 steps from 9,10-anthraquinone; coupling of II with guanidine or guanidine
 pharmacophore-substituted amines such as III followed by hydrolysis of the Me
 ester yields compds. such as I. Structure-activity relationships are
 determined for the guanidine or guanidine pharmacophore-substituted
 oxodibenzazepineacetic acids, varying the linker between the guanidine
 pharmacophore and the oxodibenzazepine and the choice of guanidine
 pharmacophore. Compound I and a second guanidine pharmacophore-substituted
 oxodibenzazepineacetic acid are found to be highly active inhibitors of the
 vitronectin receptor in vitro and are found to be bioavailable in ADME assays.


IT **326401-69-8P 326401-92-7P 443332-42-1P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)

(preparation of a guanidine or guanidine pharmacophore-substituted
 oxodibenzazepineacetic acid and lack of activity as a potential
 $\alpha\text{V}\beta 3$ receptor antagonist)


RN 326401-69-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-
 [(1-oxo-3-phenylpropyl)amino]phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX
 NAME)

PAGE 1-A




PAGE 2-A




RN 326401-92-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 443332-42-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-[[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)





IT 326398-90-7P 326399-16-0P 326399-52-4P
 326399-63-7P 326399-69-3P 326399-78-4P
 326399-83-1P 326400-55-9P 326400-65-1P
 326400-70-8P 326401-04-1P 326401-08-5P
 326401-18-7P 326401-26-7P 326401-31-4P
 326401-36-9P 326401-41-6P 326401-74-5P
 326401-97-2P 326471-38-9P 443332-00-1P
 443332-07-8P 443332-29-4P 443332-52-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of guanidine or guanidine pharmacophore-substituted
 oxodibenzazepineacetic acids as potential $\alpha\text{V}\beta\text{3}$ receptor
 antagonists)


RN 326398-90-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-3-
 pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX
 NAME)




RN 326399-16-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[(1H-benzimidazol-2-yl)methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326399-52-4 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326399-63-7 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

NAME)




RN 326399-69-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[4-(1H-imidazo[4,5-b]pyridin-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326399-78-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-2-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)





RN 326399-83-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-yl)phenyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326400-55-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326400-65-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326400-70-8 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-ylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326401-04-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[4-(1H-benzimidazol-2-yl)phenyl]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-08-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-(2-pyridinylamino)methyl]-2-thienyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 326401-18-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-(2-pyridinylamino)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)





RN 326401-26-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI)
(CA INDEX NAME)





RN 326401-31-4 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-
 [(aminoiminomethyl)amino]phenyl)methyl]amino]-2-oxoethyl]-6,11-dihydro-6-
 oxo- (9CI) (CA INDEX NAME)








RN 326401-36-9 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5-chloro-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326401-41-6 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5,6-dimethyl-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326401-74-5 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-
 [[(phenylmethoxy)carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI) (CA
 INDEX NAME)






RN 326401-97-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[4-[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]butyl]- (9CI) (CA INDEX NAME)



RN 326471-38-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(aminoiminomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 443332-00-1 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-

yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 443332-07-8 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[3-(1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 443332-29-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-
[[[(phenylmethyl)amino]carbonyl]oxy]phenyl]methyl]amino]ethyl]- (9CI) (CA
INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 443332-52-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[trans-4-(1H-benzimidazol-2-
ylamino)cyclohexyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



IT 326400-60-6P 326401-22-3P 326408-08-6P
 326408-33-7P 443331-29-1P 443331-31-5P
 443331-34-8P 443331-37-1P 443331-42-8P
 443331-47-3P 443331-50-8P 443331-53-1P
 443331-56-4P 443331-59-7P 443331-62-2P
 443331-65-5P 443331-68-8P 443331-73-5P
 443331-76-8P 443331-79-1P 443331-84-8P
 443331-87-1P 443331-90-6P 443331-93-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of guanidine or guanidine pharmacophore-substituted
 oxodibenzazepineacetic acids as potential $\alpha\text{V}\beta\text{3}$ receptor
 antagonists)


RN 326400-60-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-
 ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester
 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 326401-22-3 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-
 [(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-, methyl

ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 326408-08-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester
(9CI) (CA INDEX NAME)




RN 326408-33-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)
(CA INDEX NAME)



RN 443331-29-1 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 443331-31-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-yl)phenyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


U

RN 443331-34-8 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester

(9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 443331-37-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[4-(1H-benzimidazol-2-yl)phenyl]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)
(CA INDEX NAME)




RN 443331-42-8 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[3-(1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 443331-47-3 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


U

RN 443331-50-8 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-2-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)
 (CA INDEX NAME)





U



RN 443331-53-1 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[4-(1H-imidazo[4,5-b]pyridin-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 443331-56-4 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-[(2-pyridinylamino)methyl]-2-thienyl]methyl]amino]ethyl]-, methyl ester




RN 443331-59-7 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(aminoiminomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)
(CA INDEX NAME)



RN 443331-62-2 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5-chloro-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




PAGE 2-A




RN 443331-65-5 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5,6-dimethyl-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 443331-68-8 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-[(aminoiminomethyl)amino]phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 443331-73-5 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[4-[[[(phenylmethyl)amino]carbonyl]oxy]phenyl]methyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




PAGE 2-A




RN 443331-76-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-
[[(phenylmethoxy) carbonyl] amino] phenyl] methyl] amino] ethyl]-, methyl ester
(9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 443331-79-1 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-
[(1-oxo-3-phenylpropyl) amino] phenyl] methyl] amino] ethyl]-, methyl ester
(9CI) (CA INDEX NAME)



RN 443331-84-8 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[4-(2-pyridinylamino)phenyl]methyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443331-87-1 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-ylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 443331-90-6 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)
(CA INDEX NAME)



RN 443331-93-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[trans-4-(1H-benzimidazol-2-ylamino)cyclohexyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:115130 CAPLUS Full-text
 DN 134:178474
 TI Preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists
 IN Kling, Andreas; Geneste, Herve; Lange, Udo; Lauterbach, Arnulf; Graef, Claudia Isabella; Subkowski, Thomas; Holzenkamp, Uta; Mack, Helmut; Sadowski, Jens; Hornberger, Wilfried; Laux, Volker
 PA BASF Aktiengesellschaft, Germany
 SO PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010847	A2	20010215	WO 2000-EP7440	20000801
	WO 2001010847	A3	20011101		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19936780	A1	20010215	DE 1999-19936780	19990809
	CA 2379977	AA	20010215	CA 2000-2379977	20000801
	EP 1202988	A2	20020508	EP 2000-958347	20000801
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000013265	A	20020514	BR 2000-13265	20000801
	TR 200200357	T2	20020923	TR 2002-200200357	20000801
	JP 2003506441	T2	20030218	JP 2001-515313	20000801
	BG 106395	A	20021229	BG 2002-106395	20020206
	NO 2002000644	A	20020318	NO 2002-644	20020208
PRAI	DE 1999-19936780	A	19990809		
	WO 2000-EP7440	W	20000801		
OS	MARPAT 134:178474				
GI					



AB RZZ1R1 [I; R = group contg, ≥ 1 non-H H-bonding atom; R1 = CO₂H, or group hydrolyzable to CO₂H; Z = e.g., (hetero)annelated 2-oxo-1-benzazepin-1,5-diyl; Z1 = bond, (un)substituted NHCH₂, -OCH₂, -alkylene, -CH:CH, etc.] were prepared Thus, Me 11-methoxycarbonylmethyl-6-oxo-6,11-dihydro-5H-dibenz[b,e]azepine-5-acetate (preparation given) was amidated by N-(2-aminoethyl)pyridine-2-amine to give, after saponification, title compound II. Data for biol. activity of I were given.
 IT 326398-79-2P 326398-84-9P 326398-90-7P
 326399-01-3P 326399-07-9P 326399-11-5P
 326399-17-1P 326399-23-9P 326399-27-3P
 326399-31-9P 326399-36-4P 326399-42-2P

326399-47-7P 326399-52-4P 326399-64-8P
 326399-69-3P 326399-73-9P 326399-78-4P
 326399-83-1P 326400-13-9P 326400-18-4P
 326400-23-1P 326400-28-6P 326400-32-2P
 326400-41-3P 326400-45-7P 326400-50-4P
 326400-55-9P 326400-60-6P 326400-65-1P
 326400-70-8P 326400-74-2P 326400-79-7P
 326400-84-4P 326400-88-8P 326400-94-6P
 326400-99-1P 326401-04-1P 326401-08-5P
 326401-13-2P 326401-18-7P 326401-22-3P
 326401-26-7P 326401-32-5P 326401-36-9P
 326401-41-6P 326401-46-1P 326401-50-7P
 326401-54-1P 326401-59-6P 326401-64-3P
 326401-69-8P 326401-74-5P 326401-82-5P
 326401-92-7P 326401-97-2P 326402-06-6P
 326402-11-3P 326402-16-8P 326402-21-5P
 326402-26-0P 326402-31-7P 326402-35-1P
 326402-40-8P 326402-44-2P 326402-48-6P
 326402-52-2P 326402-57-7P 326402-62-4P
 326402-66-8P 326402-71-5P 326402-76-0P
 326402-80-6P 326402-85-1P 326402-90-8P
 326402-94-2P 326402-99-7P 326403-04-7P
 326403-08-1P 326403-13-8P 326403-18-3P
 326403-22-9P 326403-28-5P 326403-32-1P
 326403-37-6P 326403-42-3P 326403-47-8P
 326403-51-4P 326403-56-9P 326403-61-6P
 326403-66-1P 326403-71-8P 326403-76-3P
 326404-18-6P 326404-23-3P 326404-27-7P
 326404-31-3P 326404-36-8P 326471-39-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists)

RN 326398-79-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[2-(2-pyridinylamino)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 326398-84-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326398-90-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




PAGE 2-A




RN 326399-01-3 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[(4,5-dihydro-1H-imidazol-2-yl)amino]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





RN 326399-07-9 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(4,5-dihydro-1H-imidazol-2-yl)-3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 326399-06-8


CMF C27 H25 N5 O4



CM 2



CRN 64-19-7

CMF C2 H4 O2



RN 326399-11-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[1-(2-pyridinyl)-4-piperidinyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326399-17-1 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 326399-16-0


CMF C26 H22 N4 O4



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 326399-23-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[(1H-imidazo[4,5-b]pyridin-2-ylmethyl)amino]-2-oxoethyl]-6-oxo-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 326399-22-8


CMF C25 H21 N5 O4



CM 2



CRN 64-19-7

CMF C2 H4 O2





RN 326399-27-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-[[2-(2-pyridinylamino)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 326399-31-9 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-[4-(2-pyridinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)







RN 326399-36-4 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[3-[[[4-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-3-oxopropyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326399-42-2 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-[(2-pyridinylamino)methyl]-1-piperidinyl]ethyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1


CRN 326399-41-1
 CMF C29 H30 N4 O4



CM 2


CRN 64-19-7

CMF C2 H4 O2




RN 326399-47-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-
[[(phenylmethyl) amino] carbonyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX
NAME)



RN 326399-52-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326399-64-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 326399-63-7


CMF C30 H24 N4 O4 S



CM 2


CRN 64-19-7

CMF C2 H4 O2





RN 326399-69-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[4-(1H-imidazo[4,5-b]pyridin-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326399-73-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monohydrochloride




RN 326399-78-4 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-2-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326399-83-1 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-yl)phenyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326400-13-9 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(1H-imidazol-2-ylamino)-3-oxopropyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)






RN 326400-18-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[1-(2-pyridinyl)-4-piperidinyl]methyl]amino]propyl]- (9CI)
(CA INDEX NAME)




RN 326400-23-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-[[[1-(2-pyridinyl)-4-piperidinyl]methyl]amino]propyl]- (9CI) (CA INDEX NAME)




PAGE 2-A




RN 326400-28-6 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-[[[1-[(phenylmethyl)amino]carbonyl]-4-piperidinyl]methyl]amino]propyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-32-2 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[3-[[[5-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-3-oxopropyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX

NAME)

PAGE 1-A




PAGE 2-A




RN 326400-41-3 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[1-
[[(phenylmethyl) amino] carbonyl]-4-piperidinyl]methyl]amino]ethyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-45-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-[[[(phenylmethyl)amino]carbonyl]amino]methyl]phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-50-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinylamino)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326400-55-9 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-60-6 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326400-65-1 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326400-70-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-ylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326400-74-2 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[3-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326400-79-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[(1H-benzimidazol-2-ylamino)methyl]-1-piperidinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 326400-84-4 CAPLUS



CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[2-(2-pyridinylamino)-4-thiazolyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 326400-88-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[2-(2-pyridinylamino)-5-thiazolyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 326400-94-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 326400-93-5


CMF C23 H22 N6 O4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 326400-99-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[2-[(aminoiminomethyl)amino]-5-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326401-04-1 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[4-(1H-benzimidazol-2-yl)phenyl]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 326401-08-5 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-[(2-pyridinylamino)methyl]-2-thienyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 326401-13-2 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[methyl[2-(2-pyridinylamino)ethyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




PAGE 2-A




RN 326401-18-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-(2-pyridinylamino)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 326401-22-3 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 326401-26-7 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI)
 (CA INDEX NAME)



PAGE 2-A




RN 326401-32-5 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(aminoiminomethyl)amino]phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 326401-31-4
CMF C26 H25 N5 O4

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 326401-36-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5-chloro-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 326401-41-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5,6-dimethyl-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326401-46-1 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[3-(2-pyridinylamino)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326401-50-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-[2-(2-pyridinylamino)ethyl]-1-piperidinyl]ethyl]-, methyl ester (9CI). (CA INDEX NAME)



PAGE 1-A





PAGE 2-A





RN 326401-54-1 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-[2-(2-pyridinylamino)ethyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN	326401-59-6	CAPLUS
CN	5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[3-[2-(2-pyridinylamino)ethyl]-1-pyrrolidinyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)	





RN 326401-64-3 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[3-[2-(2-pyridinylamino)ethyl]-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME) .





RN 326401-69-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-[(1-oxo-3-phenylpropyl)amino]phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326401-74-5 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-
 [[(phenylmethoxy) carbonyl] amino] phenyl] methyl] amino] ethyl]- (9CI) (CA
 INDEX NAME)







RN 326401-82-5 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[5-
[[[(phenylmethyl)amino]carbonyl]amino]pentyl]- (9CI) (CA INDEX NAME)

RN 326401-92-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-[[4-
[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methoxy]ethyl]- (9CI) (CA
INDEX NAME)


RN 326401-97-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[4-[4-
[[[(phenylmethyl)amino]carbonyl]amino]phenyl]butyl]- (9CI) (CA INDEX
NAME)




RN 326402-06-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(4-methyl-1H-
imidazol-1-yl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-11-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(4-methyl-1-
piperazinyl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-16-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[(3-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-21-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-26-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[1-methyl-2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 326402-31-7 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[1-ethyl-2-pyrrolidinyl)methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-35-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(4-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 326402-40-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-44-2 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[2-(diethylamino)ethyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-48-6 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[4-[2-(diethylamino)ethyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo-

morpholinyl)ethyl]-1-piperazinyl]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326402-52-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-57-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[(2-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-62-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-66-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[3-(dibutylamino)propyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)





RN 326402-71-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-76-0 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[4-[3-(4-morpholinyl)propyl]-1-piperazinyl]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 326402-80-6 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(2-methyl-1H-imidazol-1-yl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-85-1 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[(4-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-90-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[(1-methyl-4-piperidinyl)amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 326402-94-2 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[2-(1-piperidinyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 326402-99-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-[3-(1-pyrrolidinyl)propyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

CH₂-CO₂H


RN 326403-04-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-08-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[3-(dimethylamino)propyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-13-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[2-(dipropylamino)ethyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-18-3 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-[2-(1-piperidinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326403-22-9 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[3-(dipropylamino)propyl]-1-

piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)





RN 326403-28-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(dibutylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-32-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326403-37-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[3-(diethylamino)propyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-42-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326403-47-8 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(dimethylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-51-4 CAPLUS



CN Propanoic acid, 3-[5,6-dihydro-6-oxo-5-[2-oxo-2-[[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-11H-dibenz[b,e]azepin-11-ylidene]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A








RN 326403-56-9 CAPLUS
 CN Propanoic acid, 3-[5,6-dihydro-6-oxo-5-[2-oxo-2-[[[4-
 [[[(phenylmethyl) amino] carbonyl] amino] phenyl] methyl] amino] ethyl]-11H-
 dibenz[b,e]azepin-11-ylidene]- (9CI) (CA INDEX NAME)




RN 326403-61-6 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-
 [[[4-[[[(phenylmethyl) amino] carbonyl] amino] phenyl] methyl] amino] ethyl]-,
 methyl ester (9CI) (CA INDEX NAME)





RN 326403-66-1 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-
 [[[4-[[[(phenylmethyl) amino] carbonyl] amino] phenyl] methyl] amino] ethyl]-
 (9CI) (CA INDEX NAME)








RN 326403-71-8 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[2-(2-pyridinylamino)ethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 326403-76-3 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[2-(2-pyridinylamino)ethyl]amino]ethyl]-, monosodium salt (9CI) (CA INDEX NAME)



RN 326404-18-6 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[[4-[[[4-(1H-benzimidazol-2-yl)phenyl]methyl]amino]carbonyl]-2-thiazolyl]methyl]-6,11-dihydro-6-oxo-(9CI) (CA INDEX NAME)




PAGE 2-A




RN 326404-23-3 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[4-[(2-pyridinylamino)methyl]-1-piperidinyl]carbonyl]-2-thiazolyl]methyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326404-27-7 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[[4-

[[[(phenylmethyl)amino]carbonyl]amino]phenyl)methyl]amino]carbonyl]-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 326404-31-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[[4-[(2-pyridinylamino)methyl]phenyl)methyl]amino]carbonyl]-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)



RN 326404-36-8 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[[4-[(2-pyridinylamino)methyl]-2-thienyl]methyl]amino]carbonyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 326471-39-0 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(aminoiminomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate (9CI)
 (CA INDEX NAME)


CM 1

CRN 326471-38-9
 CMF C24 H22 N4 O4 S



CM 2

CRN 64-19-7
CMF C2 H4 O2




IT 326407-89-0P 326407-94-7P 326407-99-2P
326408-04-2P 326408-08-6P 326408-13-3P
326408-23-5P 326408-28-0P 326408-33-7P
326408-41-7P 326408-46-2P 326408-54-2P
326410-02-0P 326410-07-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of oxobenzazepinealkanoates and analogs as integrin receptor
antagonists)


RN 326407-89-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[(4-carboxy-2-thiazolyl)methyl]-
6,11-dihydro-6-oxo-, α -(1,1-dimethylethyl) ester (9CI) (CA INDEX
NAME)





RN 326407-94-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[[4-(ethoxycarbonyl)-2-thiazolyl]methyl]-6,11-dihydro-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 326407-99-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[2-(2-pyridinylamino)ethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 326408-04-2 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 326408-08-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326408-13-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 326408-23-5 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(aminothioxomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326408-28-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(aminoiminomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326408-33-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)
(CA INDEX NAME)




RN 326408-41-7 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(1H-imidazol-2-ylamino)-3-oxopropyl]amino]-2-oxoethyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326408-46-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[5-
[(hydroxyamino)iminomethyl]-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo-,
methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 326408-54-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[5-
[[[(phenylmethyl)amino]carbonyl]amino]pentyl]-, methyl ester (9CI) (CA
INDEX NAME)




RN 326410-02-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-(1-piperazinyl)ethyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 326410-01-9


CMF C23 H25 N3 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 326410-07-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-[(phenylmethyl)amino]carbonyl]-1-piperazinyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1989:632774 CAPLUS Full-text
 DN 111:232774
 TI Preparation of tricyclic lactams and analogs as muscarinic antagonists
 IN Turconi, Marco; Donetti, Arturo; Cereda, Enzo; Quintero, Myrna Gil;
 Schiavi, Giovanni Battista; Micheletti, Rosamaria
 PA Istituto De Angeli S.p.A., Italy
 SO Eur. Pat. Appl., 46 pp.
 CODEN: EPXXDW

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 309422	A2	19890329	EP 1988-830374	19880919
	EP 309422	A3	19900110		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DD 282689	A5	19900919	DD 1988-319831	19880915
	DK 8805226	A	19890322	DK 1988-5226	19880920
	FI 8804305	A	19890322	FI 1988-4305	19880920
	NO 8804174	A	19890322	NO 1988-4174	19880920
	JP 01132567	A2	19890525	JP 1988-236178	19880920
	AU 8822380	A1	19890323	AU 1988-22380	19880921
PRAI	IT 1987-21978	A	19870921		

OS MARPAT 111:232774

GI For diagram(s), see printed CA Issue.

AB Title compds. I [R = H, halo; X = N, CH; W = NHCO, CH:CH, (CH₂)₂, O, S; R₁ = H, C₁-4 alkyl; n = 0, 1; Y = S, CH; A = C, N; B = CH when A ≠ N, CO₂, CO, CH₂; m = 0-3; Z = NH, CO, CO₂, CH, bond; p, q = 0, 1; Q = (homo)piperazinyl, piperidinyl, trotyl, tetrahydroprimidinyl, the above groups may be substituted by a C₁-4 alkyl or an amino; R = CR₂:NR₃; R₂ = H, C₁-4 alkyl, (C₁-4 alkyl- or Ph-substituted) amino; R₃ = C₁-8 alkyl, H (provided that the bond of QR is a C-C bond or AB = C:CH); R₂R₃ = atoms to form a 5-membered ring] are prepared for treatment of motility disorders of the gastrointestinal or urogenital tract and peptic ulcer disorders. A mixture of 5,10-dihydro-5-[2-piperazin-1-yl)acetyl]-11H-dibenzo[b,e][1,4]-diazepin-11-one and H₂NC(:NH)SMe.H₂SO₄ in EtOH was refluxed to give the 4-guanylpiperazinyl analog isolated as its 2 HCl salt. The latter salt showed a dissociation constant (K_D) of 6 nM for displacement of 3H-pirenzepine from cerebral cortex homogenate of rats. Tablets were formulated containing I 20, lactose 247, cornstarch 30, and Mg stearate 3 mg.


IT 122860-22-4P 122860-34-8P 122860-50-8P
 122860-58-6P 122860-66-6P 122860-68-8P
 122882-81-9P 122882-85-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of muscarinic antagonists)

RN 122860-22-4 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[(5,6-dihydro-6-oxo-11H-dibenz[b,e]azepin-11-ylidene)acetyl]oxy]-, phenylmethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 122860-34-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-,
[1-[(phenylmethoxy)carbonyl]-4-piperidinyl]methyl ester (9CI) (CA INDEX
NAME)




RN 122860-50-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-,
1-[imino(nitroamino)methyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)




RN 122860-58-6 CAPLUS

CN Acetic acid, (5,6-dihydro-6-oxo-11H-dibenz[b,e]azepin-11-ylidene)-, 1-[imino(nitroamino)methyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)




RN 122860-66-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-, 1-[imino(nitroamino)methyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)




RN 122860-68-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-, 1,4,5,6-tetrahydro-2-(nitroamino)-5-pyrimidinyl ester (9CI) (CA INDEX NAME)




RN 122882-81-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-, 1-[(phenylmethoxy)carbonyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)



RN 122882-85-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-,
1-[imino(nitroamino)methyl]-3-piperidinyl ester (9CI) (CA INDEX NAME)



IT 122882-58-0P 122882-61-5P 122882-62-6P

122882-63-7P 122882-64-8P 122882-66-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as muscarinic antagonist)


RN 122882-58-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-,
1-(aminoiminomethyl)-4-piperidinyl ester, monoformate (9CI) (CA INDEX
NAME)

CM 1

CRN 122882-57-9


CMF C22 H24 N4 O3



CM 2


CRN 64-18-6

CMF C H2 O2



RN 122882-61-5 CAPLUS

CN Acetic acid, (5,6-dihydro-6-oxo-11H-dibenz[b,e]azepin-11-ylidene)-, 1-(aminoiminomethyl)-4-piperidiny] ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 122882-62-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-,


1-(aminoiminomethyl)-4-piperidinyl ester, monohydrochloride (9CI) (CA
INDEX NAME)



RN 122882-63-7 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-,
1-(aminoiminomethyl)-3-piperidinyl ester, monohydrochloride (9CI) (CA
INDEX NAME)



RN 122882-64-8 CAPLUS
CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-,
2-amino-1,4,5,6-tetrahydro-5-pyrimidinyl ester, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 122882-66-0 CAPLUS
 CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-,
 [1-(aminoiminomethyl)-4-piperidinyl]methyl ester, monoformate (9CI) (CA
 INDEX NAME)

CM 1

CRN 122882-65-9
 CMF C22 H24 N4 O3




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1987:4907 CAPLUS Full-text
 DN 106:4907
 TI Preparation of morphanthridine analogs as pharmaceuticals
 IN Senda, Shigeo; Ueda, Takashi; Nakagawa, Kazuyuki
 PA Otsuka Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 21 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61167663	A2	19860729	JP 1985-7854	19850118
	JP 06065664	B4	19940824		
PRAI	JP 1985-7854		19850118		
GI					



I


AB Analogs of morphanthridine (I) are prepared and are useful in the treatment of arrhythmia, inflammation, diuresis, and ulcer. Thus, I was prepared by treating 5-methyl-11-carboxy-6-oxomorphanthridine first with thionyl chloride and then with diethylaminoethanol. Thirty-four I analogs were prepared. The inhibitory actions of I analogs on gastric acid secretion were demonstrated. No other pharmacol. studies were described.

IT 105671-18-9P 105671-33-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as pharmaceutical)


RN 105671-18-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 5-[2-(dimethylamino)-2-oxoethyl]-6,11-dihydro-6-oxo-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 105671-33-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 5-[2-(dimethylamino)-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



=> d l2; d his; log y
 L2 HAS NO ANSWERS
 L1 STR



G1 O,S,N
 G2 [01],[02],[03],[04],[05],[06]

Structure attributes must be viewed using STN Express query preparation.
 L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 14:58:46 ON 23 NOV 2005)

FILE 'REGISTRY' ENTERED AT 14:58:53 ON 23 NOV 2005

L1 STRUCTURE UPLOADED
 L2 QUE L1
 L3 8 S L2
 L4 204 S L2 FUL

FILE 'CAPLUS' ENTERED AT 14:59:49 ON 23 NOV 2005

L5 5 S L4

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	25.15	187.12
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.65	-3.65

STN INTERNATIONAL LOGOFF AT 15:00:41 ON 23 NOV 2005